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ince 1978 the National Toxicology Program 
(NTP) has coordinated, developed, carried out, 
and informed the public about toxicology testing 
within the federal government. For chemical carcinogen-
esis bioassays, the NTP has long used a set of standardized 
criteria for classifying the relative strength of experimental 
outcomes. These criteria have enabled the NTP to assess 
the potential carcinogenicity of nearly 600 substances. Now 
the program is launching similar criteria for assessing other 
types of adverse effects, such as damage to the immune sys-
tem, the reproductive system, and the developing organism. 
The new criteria attempt to impose a sense of unifor-
mity to different types of toxicology data. “It’s very difficult 
to develop criteria for noncancer end points,” says Nancy 
Kerkvliet, a professor of immunotoxicology at Oregon State 
University, a former member of the NTP Board of Scientific 
Counselors (BSC), and chair of the Working Group that 
reviewed the new immunotoxicity classification criteria. 
“There’s such a variety of end points. It’s difficult to rank 
them for importance.” The NTP, aware of this inherent dif-
ficulty, hopes the levels-of-evidence criteria will allow better 
transference to public health decisions.Decades  of  cancer  studies  have 
provided a widely accepted template for 
assessing and evaluating the relative com-
parability and importance of various can-
cer study outcomes. First created in 1983, 
the NTP’s 5-tiered classification system 
describes the strength of evidence for 
conclusions for NTP chemical carcino-
genesis studies. These classifications—
which include 1) clear evidence, 2) some 
evidence, 3) equivocal evidence, 4) no evi-
dence, and 5) inadequate study—are used 
to frame the conclusions per sex/species in 
the experiment cited in each NTP tech-
nical report. “These classifications have 
stood the test of time,” says Paul Foster, 
NTP discipline leader for reproductive 
and developmental toxicology.
The strongest findings, which can be 
considered “clear evidence” of carcino-
genic activity, are demonstrated by studies 
that are interpreted as showing a dose-
related increase of malignant neoplasms, 
a combination of malignant and benign 
neoplasms, or benign neoplasms if there 
is any indication that such tumors could 
progress to malignancy. To help NTP staff 
decide on borderline cases, there are 15 
additional reference points, or factors to be 
considered in addressing various aspects, 
such as “presence or absence of dose rela-
tionships” and “statis  tical significance of 
the observed tumor increase.” Using these 
criteria allows NTP staff to better develop 
consistent conclusions for multiple studies 
of the same substance and for compar-
ing different chemicals under these same 
criteria.  
The  NTP  classification  system  is 
applied only to those studies conducted 
by the program. The 5 designations are 
intended to be solely a conclusion about 
whether a substance may potentially pose 
a carcinogenic hazard to humans. They are 
not intended to describe a carcinogenic risk 
to human health, but to be an integral part 
of the more formal risk assessment pro-
cess that takes place at state and other fed-
eral agencies. This formal risk assessment 
requires additional evaluation of factors 
such as specific doses, routes, and likeli-
hood of exposure as well as a whole host 
of other information including published 
bioassays and toxicology studies conducted 
by different organizations. 
Similar Classifications for Other 
Toxicologic Outcomes
The long-term successful use of the carci-
nogenicity classification system suggested 
to NTP leaders that they could develop 
similar classifications for other toxicologic 
outcomes for which there were adequate 
experimental  and  scientific  data—in 
particular, toxicity to the immune and 
reproductive systems and the developing 
organism. 
To start the process, Foster and Dori 
Germolec, NTP leader for immuno-
toxicology, consulted with internal toxi-
cologists and external colleagues to devise 
wording for 5 categories of evidence. 
Next, the NTP BSC, which routinely pro-
vides scientific advice to the organization, 
formed two Working Groups compris-
ing members from federal and state regu-
latory agencies, academia, corporations, 
and nongovernment organizations. “The 
composition of the two Working Groups 
was carefully developed to include indi-
viduals who are experts in the conduct 
of immuno  toxicology or reproductive/
develop  mental studies, and indiv  iduals 
who might be users of the NTP studies 
such as regulatory agencies, in order to get 
critical input on the potential utility and 
applicability of the proposed criteria,” says 
Mary Wolfe, director of the NTP Office of 
Liaison, Policy, and Review.
These  Working  Groups  reviewed 
the draft NTP criteria, and individuals 
applied the criteria to sample data sets, 
then compared their results as a group. 
The reports and recommendations of the 
Working Groups were presented to the 
BSC in November 2008. After review 
of the criteria by the BSC, Foster pre-
sented the Working Group reports to the 
NTP Executive Committee, whose mem-
bers are drawn from 8 federal agencies. 
The new NTP criteria will be presented 
at the Society of Toxicology meeting in 
Baltimore, Maryland, in March 2009. 
Putting the New Categories 
into Practice 
The criteria may be applied to chemi-
cals using findings from previous NTP 
studies as a practice exercise, Germolec 
says. However, the criteria will not be 
used to evaluate new NTP reports until 
late 2009 and early 2010, when results 
are expected for gum guggul (an oleo-
resin used as a dietary supplement), res-
veratrol (an antioxidant produced by 
grape plants), tetrachloroazobenzene (a 
pesticide by-product), and an unnamed 
endocrine-disrupting fungicide (because 
the chemical is undergoing blind tests, its 
name will be released only upon comple-
tion of the study). 
Once added to the developmental, 
reproductive, and immune system tox-
icity reports published by the NTP, the 
criteria will give readers a more standard-
ized vocabulary for understanding the 
NTP’s interpretation of study results and 
better ability to compare results between 
chemicals. Among those who use the NTP 
reports—and base decisions upon them—
are regulators, policymakers, politicians, 
lawyers, and advocacy groups. 
Some observers suggest the criteria 
may require further adjustments. David 
Wegman, a professor of epidemiology at 
the University of Massachusetts Lowell and 
a BSC member, questions the “some evi-
dence” category covering the broad swath 
between “clear” and “equivocal” evidence. 
“It’s an awful big range to cover with the 
word ‘some,’” Wegman says. He suggests 
possibly dividing that category into two 
better-defined categories. 
Wegman also says that many details in 
the exact language used in the criteria still 
need to be refined. He admits that even 
he, as a long-term expert in the field of 
epidemiology, didn’t understand some of 
the terms as they were used by experts in 
other fields during the Working Group 
and BSC meetings. Because NTP reports 
are used by regulators and scientists in a 
variety of fields, he says, it is important 
that all users be able to understand the lan-
guage describing the conclusions. And he 
believes others will face greater challenges. 
“The level of [broad-based] health literacy 
in our population is extremely poor,” he 
says. “So the language used has to be easily 
understood.” 
NTP staff have refined the terms and 
language used to address concerns such as 
Wegman’s. In the preamble to each of the 
criteria documents, which will be available 
on the NTP website (http://ntp.niehs.nih.
gov/) in early March, the NTP defines each 
of the 5 criteria as they apply to the indi-
vidual areas of immunotoxicity, reproduc-
tive toxicity, and developmental tox  icity. 
The documents include examples of the 
types of findings that support the assign-
ment of one criterion over another and 
define key terms such as “dose-related.” 
The documents also point out the differ-
ences between hazard assessment—which is 
the intended use of these classifications—
and the broader, more comprehensive pro-
cess of formal risk assessment. 
On a related note, there “was a sig-
nificant amount of debate about the use 
of dose information [in applying the 
criteria],” Foster says. Dose information 
typically falls into the domain of risk 
assessment, but there’s a majority agree-
ment so far that some kind of exposure 
information is needed if the criteria are 
to be applied realistically. “Hazard infor-
mation without some kind of dose infor-
mation is scary,” says Kim Boekelheide, 
a professor of medical science at Brown 
University and a member of the Working 
Group that reviewed the reproductive and 
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technical report will include information 
about the lowest dose at which an adverse 
effect was observed as well as complete 
details used to reach conclusions. 
The NTP is looking into how to 
develop criteria for other organ and sys-
tem toxicities, such as neurologic, gastro-
enterologic, cardio  vascular, and pulmonary 
end points. For now, the NTP and many 
of those who use its reports look forward 
to introducing and using their classifica-
tions for immuno  toxicity, reproductive 
toxicity, and developmental toxicity. 
“Right now we don’t have anything 
in the way of categories of evidence,” says 
Edward Carney, technical leader for devel-
opmental, reproductive, and general toxi-
cology at The Dow Chemical Company 
and chair of the reproductive and develop-
mental toxicity Working Group. “In the 
end this system will be better than what 
we have now.” James Donald, chief of the 
Reproductive Toxicology and Epidemiology 
Section at the California EPA Office of 
Environmental Health Hazard Assessment 
and a member of the reproductive and 
developmental toxicity Working Group, 
agrees: “I think for NTP’s purposes it’s 
going to be very useful.” 
Bob Weinhold
Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r  3 | March 2009   A 115
Spheres of Influence | Building on Success 
 
Timeline for Noncancer Evaluation Criteria
November 2008 February 2009 March 2009 Late 2009/Early 2010
The NTP Board of Scientific Counselors 
voted to accept three Working Group 
reports addressing the establishment 
of new evaluation criteria for future 
NTP immuno  toxicology, reproductive, 
and developmental studies.
The NTP finalized the
“levels of evidence” 
statements defining 
the three sets of criteria, 
incorporating recommen-
dations from its Board 
of Scientific Counselors 
and Executive Committee.
The proposed evaluation 
criteria will be formally 
presented to attendees at 
the Society for Toxicology 
48th Annual Meeting in 
Baltimore, Maryland.
The NTP expects to begin applying 
the immuno  toxicology criteria to 
studies for peer review by the end 
of 2009. The first reproductive and 
developmental studies featuring 
the new criteria could appear as 
early as early as 2010.